首页> 外文期刊>Biomedical Chromatography: An International Journal Devoted to Research in Chromatographic Methodologies and Their Applications in the Biosciences >A validated LC- MS/MS method for the quantification of capivasertib in dog plasma: Application to its pharmacokinetics study
【24h】

A validated LC- MS/MS method for the quantification of capivasertib in dog plasma: Application to its pharmacokinetics study

机译:用于定量Capivasertib在狗血浆中的验证的LC-MS / MS方法:在其药代动力学研究中的应用

获取原文
获取原文并翻译 | 示例
       

摘要

In this study, a simple and reliable liquid chromatography tandem mass spectrometric method was first developed for the determination of capivasertib in dog plasma with ipatasertib as internal standard. The plasma samples were deproteinated using aceto-nitrile. An Acquity BEH C_18 column (1.7 pm, 2.1x50 mm) maintained at 40°C was used for chromatographical separation, with water containing 0.1% formic acid and acetonitrile as mobile phase. Multiple reaction monitoring transitions were m/z 429.2 > 135.1 for capivasertib and m/z 458.2 > 387.2 for ipatasertib, respectively. Excellent linearity was achieved in the concentration range of 1-1,000 ng/ml with a correlation coefficient of >0.9981. The lower limit of quantification was 1 ng/ml. The extraction recovery of capivasertib from dog plasma was >85.81% and no significant matrix effect was found. The intra- and inter-day precision was <9.58% and the accuracy ranged from -10.60% to 12.50%. The validated method was further applied to the pharmacokinetic study of capivasertib in dog plasma after single oral (5 mg/kg) and intravenous (1 mg/kg) administrations. The results revealed that capivasertib was rapidly absorbed into plasma with good bioavailability (47.04%) and low clearance.
机译:在该研究中,首先开发了一种简单可靠的液相色谱串联质谱法,用于使用iPatasertib作为内标测定Capivasertib中的Capivasertib。使用丙酮腈脱落等离子体样品。在40℃下保持在40℃的ACCATESH C_18柱(1.7 PM,2.1X50mm)用于色谱分离,水含有0.1%甲酸和乙腈作为流动相的水。对于Capivasertib和M / Z 458.2> 387.2,分别为M / Z 429.2> 387.2分别用于IPatasertib的多重反应监测转变。在1-1,000ng / ml的浓度范围内实现优异的线性,具有> 0.9981的相关系数。定量下限为1ng / ml。来自狗血浆的Capivasertib的提取恢复> 85.81%,发现没有明显的基质效应。日内和日间精度<9.58%,精度为-10.60%至12.50%。验证的方法进一步应用于单口口服(5mg / kg)和静脉内(1mg / kg)给药后狗血浆中Capivasertib的药代动力学研究。结果表明,Capivasertib迅速吸收到血浆中,具有良好的生物利用度(47.04%)和低间隙。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号